ERTS Wealth Advisors LLC lifted its holdings in shares of Edwards Lifesciences Corp (NYSE:EW) by 79.2% in the 2nd quarter, HoldingsChannel reports. The fund owned 1,131 shares of the medical research company’s stock after purchasing an additional 500 shares during the period. ERTS Wealth Advisors LLC’s holdings in Edwards Lifesciences were worth $209,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of EW. TRUE Private Wealth Advisors bought a new stake in Edwards Lifesciences in the 2nd quarter worth about $26,000. Evolution Wealth Advisors LLC bought a new stake in Edwards Lifesciences in the 2nd quarter worth about $29,000. M&R Capital Management Inc. bought a new stake in Edwards Lifesciences in the 2nd quarter worth about $29,000. Next Capital Management LLC grew its position in Edwards Lifesciences by 297.7% in the 2nd quarter. Next Capital Management LLC now owns 171 shares of the medical research company’s stock worth $32,000 after purchasing an additional 128 shares in the last quarter. Finally, Tarbox Family Office Inc. grew its position in Edwards Lifesciences by 48.7% in the 2nd quarter. Tarbox Family Office Inc. now owns 177 shares of the medical research company’s stock worth $33,000 after purchasing an additional 58 shares in the last quarter. 81.46% of the stock is owned by institutional investors.

Shares of EW stock traded down $1.68 during trading on Friday, reaching $218.77. 9,131 shares of the company’s stock traded hands, compared to its average volume of 964,080. The company has a market capitalization of $45.39 billion, a P/E ratio of 46.52, a PEG ratio of 2.75 and a beta of 0.84. The company has a current ratio of 3.38, a quick ratio of 2.48 and a debt-to-equity ratio of 0.18. The firm’s 50-day moving average is $217.31 and its 200 day moving average is $190.94. Edwards Lifesciences Corp has a 1 year low of $136.44 and a 1 year high of $228.19.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, July 23rd. The medical research company reported $1.38 EPS for the quarter, beating the Zacks’ consensus estimate of $1.33 by $0.05. The company had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.04 billion. Edwards Lifesciences had a net margin of 18.29% and a return on equity of 31.25%. Edwards Lifesciences’s revenue was up 15.2% compared to the same quarter last year. During the same period in the prior year, the company posted $1.24 EPS. As a group, sell-side analysts predict that Edwards Lifesciences Corp will post 5.34 earnings per share for the current fiscal year.

A number of brokerages have issued reports on EW. Canaccord Genuity upped their price objective on shares of Edwards Lifesciences from $215.00 to $250.00 and gave the stock a “buy” rating in a research report on Wednesday, July 24th. Bank of America reaffirmed a “buy” rating and issued a $225.00 price objective (up from $215.00) on shares of Edwards Lifesciences in a research report on Wednesday, July 24th. Barclays boosted their target price on shares of Edwards Lifesciences from $160.00 to $175.00 and gave the company an “underweight” rating in a research note on Wednesday, July 24th. Morgan Stanley boosted their target price on shares of Edwards Lifesciences from $210.00 to $228.00 and gave the company an “overweight” rating in a research note on Wednesday, July 24th. Finally, Credit Suisse Group boosted their target price on shares of Edwards Lifesciences from $221.00 to $226.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and fourteen have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $206.32.

In related news, VP Catherine M. Szyman sold 1,152 shares of the company’s stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $191.70, for a total transaction of $220,838.40. Following the sale, the vice president now owns 19,162 shares of the company’s stock, valued at approximately $3,673,355.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Michael A. Mussallem sold 22,850 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $214.90, for a total transaction of $4,910,465.00. Following the sale, the chief executive officer now directly owns 95,770 shares in the company, valued at approximately $20,580,973. The disclosure for this sale can be found here. Insiders have sold a total of 181,541 shares of company stock worth $38,060,211 over the last 90 days. 1.63% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Recommended Story: How are dividend achievers different from dividend aristocrats?

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.